Tagged with Strategy,

Taiwan Will Hsu leads Sandoz operations across Taiwan, Hong Kong, and Macao, managing a portfolio spanning both generics and biosimilars in markets characterised by universal healthcare and significant budget constraints. With nearly 12 years at Sandoz, including three years in his current regional role, Hsu oversees strategic initiatives to increase biosimilar…

USA Adriana Herrera, CEO of Pierre Fabre Pharmaceuticals Inc, discusses Pierre Fabre’s dedicated expansion into the US market and the unique strategies guiding its next phase of growth. Drawing on more than two decades of leadership experience across global biopharma organizations, Herrera reflects on building a purpose-driven organization, establishing credibility beyond…

Taiwan Taiwanese biotech Caliway is trying to redefine fat reduction as measurable medicine. Founded in 2012, Caliway has advanced its first-in-class candidate CBL-514 into pivotal Phase III development in the US, following ten completed clinical studies. President Antony Hsu outlines the science behind selective adipocyte apoptosis, the regulatory strategy behind the…

LatAm Carlos Abelleyra leads Medix, a 70-year-old Mexican pharmaceutical company undergoing a major strategic transformation. Since 2024, he has diversified the firm beyond its historical obesity focus, establishing divisions in vitamins, gastrointestinal products, and women’s health. With a landmark Biocon licensing deal for GLP-1 therapies and plans to launch 30 new…

LatAm Fernando Almeida, EVP China & International Markets, discusses his global pharma career and Chiesi’s evolution into a high-performing, innovation-led group. He highlights strong double-digit growth, disciplined investment, and expansion across China and Latin America, underpinned by access-driven strategies, talent mobility, and long-term patient impact.   To become a strong and…

UAE Adeeb Al Attar leads Genpharm at a point where rare and advanced therapies in the Middle East face a more exacting test. Scale and ambition are no longer enough. What matters now is execution, credibility, and the ability to move innovation through complex healthcare systems without losing focus. In this…

USA Neil F. McFarlane, President and CEO of Zevra Therapeutics, reflects on how his experiences in clinical practice, military service, and leadership roles across biotech and mid-sized pharma come together and led him to this moment. Under McFarlane, Zevra is driven by the urgency of patient needs and engaging with patient…

France Kyowa Kirin’s new head for France and Benelux steps into the role at a time when rare diseases, regulatory expectations and scientific modalities are all shifting at speed. In this interview, Aurelie-Anne Chausse reflects on the recent strategic transition toward a fully rare-disease-focused organisation, the growing pressure to identify patients…

Taiwan Jayashri Kulkarni Managing Director of Johnson & Johnson Taiwan, brings 27 years of experience across pharmaceuticals and medical technology in Asia Pacific. Since assuming her Taiwan role , she has focused on outcome-based healthcare, patient advocacy, and leadership development, bringing a perspective that bridges emerging market innovation with healthcare system…

Taiwan With Takeda preparing for global leadership change and Taiwan rapidly upgrading its innovation and access frameworks, General Manager Alexis Lin is navigating one of the most pivotal periods in the affiliate’s 64-year history. Drawing on a career that began far from pharma, she has reshaped Takeda Taiwan into a regional…

Taiwan Nick Wang, General Manager of Daiichi Sankyo Taiwan, has more than 25 years’ experience across clinical research and commercial leadership. Since joining the company in 2020, he has led the build-out of its oncology business while steering the affiliate’s transition to a full-function organisation, with a clear focus on lifecycle…

France Biogen France is operating at a moment of profound change, where rapid advances in neurology, immunology and rare diseases intersect with shifting global dynamics on investments to innovation and new expectations of industry-public collaboration. In this interview, Marina Vasiliou reflects on how these forces are reshaping the affiliate’s mission, the…